OwlTail

Cover image of Sandip Patel

Sandip Patel

8 Podcast Episodes

Latest 6 Nov 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

PODCAST-GRACEcast- Dr. Sandip Patel- Emerging Molecular Targets in NSCLC- KRAS

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Dr. Sandip Patel discusses emerging Molecular Targets in NSCLC- KRAS

6mins

12 May 2021

Episode artwork

GRACEcast- Dr. Sandip Patel- Emerging Molecular Targets in NSCLC- EGFR Exon 20

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Dr. Sandip Patel discusses emerging molecular targets in NSCLC -- EGFR Exon 20

6mins

5 May 2021

Similar People

Episode artwork

Kathryn Beal, MD, and Sandip Patel, MD - Challenges, Controversies, and Opportunities in the Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases: Working Together to Improve Patient Outcomes

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/PPF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Central nervous system (CNS) metastases occur commonly in patients with lung cancer, and those patients with epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) are particularly prone to their development. Treatment of brain metastases is challenging, and there are varied perspectives among different specialists about the best approach—if, when, and how to use local therapies, systemic therapies, or different treatment modalities in combination or sequence, etc. Clinical trials are underway to try to answer some of these critical questions about which treatment strategies yield the best results for these patients. This PeerView Live MasterClass and Practicum on-demand educational activity features a panel of multidisciplinary experts in EGFR-mutant lung cancer and CNS metastases who discuss the evolving evidence, clinical challenges, and practicalities of patient care. Real cases are debated from multiple perspectives, with an emphasis on information and guidance relevant for radiation oncologists. Upon completion of this activity, participants should be better able to: Describe molecular pathways that drive malignancy in lung cancer and the oncogenic activation of tyrosine kinases, such as mutations in EGFR, and the epidemiology and presentation of CNS metastases in EGFR-mutant lung cancer, Discuss the mechanisms of action, characteristics, and safety/efficacy profiles of the various EGFR TKIs available for the treatment of EGFR-mutant NSCLC throughout the continuum of advanced disease, including in patients with CNS metastases, Summarize the efficacy and safety data of available and emerging treatment strategies used in the management of brain or leptomeningeal metastases in patients with EGFR-mutant NSCLC, including the use of local therapies such as radiation, systemic therapies such as EGFR TKIs, and sequential/combination treatment approaches, Implement individualized treatment plans for patients with EGFR-mutant lung cancer with CNS metastases, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care

1hr 18mins

11 Nov 2019

Episode artwork

Kathryn Beal, MD, and Sandip Patel, MD - Challenges, Controversies, and Opportunities in the Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases: Working Together to Improve Patient Outcomes

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/PPF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Central nervous system (CNS) metastases occur commonly in patients with lung cancer, and those patients with epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) are particularly prone to their development. Treatment of brain metastases is challenging, and there are varied perspectives among different specialists about the best approach—if, when, and how to use local therapies, systemic therapies, or different treatment modalities in combination or sequence, etc. Clinical trials are underway to try to answer some of these critical questions about which treatment strategies yield the best results for these patients. This PeerView Live MasterClass and Practicum on-demand educational activity features a panel of multidisciplinary experts in EGFR-mutant lung cancer and CNS metastases who discuss the evolving evidence, clinical challenges, and practicalities of patient care. Real cases are debated from multiple perspectives, with an emphasis on information and guidance relevant for radiation oncologists. Upon completion of this activity, participants should be better able to: Describe molecular pathways that drive malignancy in lung cancer and the oncogenic activation of tyrosine kinases, such as mutations in EGFR, and the epidemiology and presentation of CNS metastases in EGFR-mutant lung cancer, Discuss the mechanisms of action, characteristics, and safety/efficacy profiles of the various EGFR TKIs available for the treatment of EGFR-mutant NSCLC throughout the continuum of advanced disease, including in patients with CNS metastases, Summarize the efficacy and safety data of available and emerging treatment strategies used in the management of brain or leptomeningeal metastases in patients with EGFR-mutant NSCLC, including the use of local therapies such as radiation, systemic therapies such as EGFR TKIs, and sequential/combination treatment approaches, Implement individualized treatment plans for patients with EGFR-mutant lung cancer with CNS metastases, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care

1hr 18mins

11 Nov 2019

Most Popular

Episode artwork

Kathryn Beal, MD, and Sandip Patel, MD - Challenges, Controversies, and Opportunities in the Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases: Working Together to Improve Patient Outcomes

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/PPF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Central nervous system (CNS) metastases occur commonly in patients with lung cancer, and those patients with epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) are particularly prone to their development. Treatment of brain metastases is challenging, and there are varied perspectives among different specialists about the best approach—if, when, and how to use local therapies, systemic therapies, or different treatment modalities in combination or sequence, etc. Clinical trials are underway to try to answer some of these critical questions about which treatment strategies yield the best results for these patients. This PeerView Live MasterClass and Practicum on-demand educational activity features a panel of multidisciplinary experts in EGFR-mutant lung cancer and CNS metastases who discuss the evolving evidence, clinical challenges, and practicalities of patient care. Real cases are debated from multiple perspectives, with an emphasis on information and guidance relevant for radiation oncologists. Upon completion of this activity, participants should be better able to: Describe molecular pathways that drive malignancy in lung cancer and the oncogenic activation of tyrosine kinases, such as mutations in EGFR, and the epidemiology and presentation of CNS metastases in EGFR-mutant lung cancer, Discuss the mechanisms of action, characteristics, and safety/efficacy profiles of the various EGFR TKIs available for the treatment of EGFR-mutant NSCLC throughout the continuum of advanced disease, including in patients with CNS metastases, Summarize the efficacy and safety data of available and emerging treatment strategies used in the management of brain or leptomeningeal metastases in patients with EGFR-mutant NSCLC, including the use of local therapies such as radiation, systemic therapies such as EGFR TKIs, and sequential/combination treatment approaches, Implement individualized treatment plans for patients with EGFR-mutant lung cancer with CNS metastases, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care

1hr 18mins

11 Nov 2019

Episode artwork

Dr. Sandip Patel (Pt 2): Advances and Impasses in Precision Medicine for Cancer

The Beacon

Dr. Jack West speaks with Dr. Sandip Patel about how molecular oncology has changed outcomes in cancer care, but also how we face great difficulty in getting the knowledge & practice patterns out to communities.

31mins

12 Jul 2019

Episode artwork

Dr. Sandip Patel (Pt 1): The Importance of Language & Good Communication to Connect with Patients

The Beacon

Drs. Sandip Patel & host Jack West track his early interest in medicine and even oncology & the importance of good communication & value of effective use of language when working with patients with cancer.

20mins

10 Jul 2019

Episode artwork

Dr. Sandip Patel (Pt 1): The Importance of Language & Good Communication to Connect with Patients

The Beacon

Drs. Sandip Patel & host Jack West track his early interest in medicine and even oncology & the importance of good communication & value of effective use of language when working with patients with cancer.

20mins

10 Jul 2019